Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
复制标题
DOI：
10.1148/radiol.2016151155
复制
发表时间：
2016-10
期刊：
影响因子：
19.7
通讯作者：
Moy LA
中科院分区：
文献类型：
--
作者：
Melsaether AN;Raad RA;Pujara AC;Ponzo FD;Pysarenko KM;Jhaveri K;Babb JS;Sigmund EE;Kim SG;Moy LA
比较氟18（18 F）氟脱氧葡萄糖（FDG）联合正电子发射断层扫描（PET）和磁共振（MR）成像与18 F FDG联合PET和计算机断层扫描（CT）在乳腺癌患者器官特异性转移性病变检测和辐射剂量方面的差异。从2012年7月至2013年10月，这项机构审查委员会批准的符合HIPAA的前瞻性研究纳入了51例乳腺癌患者（50例女性;平均年龄56岁;范围32 - 76岁; 1例男性;年龄70岁），这些患者在未增强PET/CT后完成了PET/MR成像，采用弥散加权和造影剂增强序列。获得参与研究的书面知情同意书。两名独立阅片员记录每种模式的病变部位和数量。影像学和临床随访，在两个案件的共识，作为参考标准。30例患者有242个远处转移病灶，17例患者有18个乳腺癌，8例患者有19个阳性腋窝淋巴结。在每例患者的基础上，PET/MR弥散加权成像和对比增强序列显示了远处转移。（阅片人1和2的30/30 [100%]）和腋窝（阅片人1为88 [100%]，阅片人2为7/8 [88%]）转移性疾病的发生率与未增强PET/CT相似（远端转移性疾病：29例中的28例[96%]，阅片人3和4，P = 0.50;腋窝转移性疾病：8个中的7个[88%]用于读取器3和4，P>.99），在乳腺癌的检测中优于PET/CT（阅片人1和2的17/17 [100%] vs阅片人3的11/17 [65%]和阅片人4的10/17 [59%]; P <.001）。PET/MR成像显示对肝脏的敏感性增加（阅片者1为40/40 [100%]，阅片者2为32/40 [80%]，阅片者3为30/40 [75%]，阅片者4为28/40 [70%]; P <0.001）和骨（阅读者1为105/107 [98%]，阅读者2为102/107 [95%]，阅读者3为106/107 [99%]，阅读者4为93/107 [87%]; P = 0.012）转移，51例患者中有5例（10%）显示脑转移。PET/CT对肺转移的敏感性有增加的趋势（阅片人1为23例中的20例[87%]，阅片人2为23例中的17例[74%]，阅片人3为23例中的23例[100%]，阅片人4为23例中的22例[96%]; P = 0.065）。剂量平均减少50%（P <0.001）。在乳腺癌患者中，与PET/CT相比，PET/MR成像可能对肝脏和可能的骨转移产生更好的灵敏度，但对肺转移没有更好的灵敏度，辐射剂量约为一半。
To compare fluorine 18 (18F) fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and magnetic resonance (MR) imaging with 18F FDG combined PET and computed tomography (CT) in terms of organ-specific metastatic lesion detection and radiation dose in patients with breast cancer. From July 2012 to October 2013, this institutional review board–approved HIPAA-compliant prospective study included 51 patients with breast cancer (50 women; mean age, 56 years; range, 32–76 years; one man; aged 70 years) who completed PET/MR imaging with diffusion-weighted and contrast material–enhanced sequences after unenhanced PET/CT. Written informed consent for study participation was obtained. Two independent readers for each modality recorded site and number of lesions. Imaging and clinical follow-up, with consensus in two cases, served as the reference standard. There were 242 distant metastatic lesions in 30 patients, 18 breast cancers in 17 patients, and 19 positive axillary nodes in eight patients. On a per-patient basis, PET/MR imaging with diffusion-weighted and contrast-enhanced sequences depicted distant (30 of 30 [100%] for readers 1 and 2) and axillary (eight of eight [100%] for reader 1, seven of eight [88%] for reader 2) metastatic disease at rates similar to those of unenhanced PET/CT (distant metastatic disease: 28 of 29 [96%] for readers 3 and 4, P = .50; axillary metastatic disease: seven of eight [88%] for readers 3 and 4, P > .99) and outperformed PET/CT in the detection of breast cancer (17 of 17 [100%] for readers 1 and 2 vs 11 of 17 [65%] for reader 3 and 10 of 17 [59%] for reader 4; P < .001). PET/MR imaging showed increased sensitivity for liver (40 of 40 [100%] for reader 1 and 32 of 40 [80%] for reader 2 vs 30 of 40 [75%] for reader 3 and 28 of 40 [70%] for reader 4; P < .001) and bone (105 of 107 [98%] for reader 1 and 102 of 107 [95%] for reader 2 vs 106 of 107 [99%] for reader 3 and 93 of 107 [87%] for reader 4; P = .012) metastases and revealed brain metastases in five of 51 (10%) patients. PET/CT trended toward increased sensitivity for lung metastases (20 of 23 [87%] for reader 1 and 17 of 23 [74%] for reader 2 vs 23 of 23 [100%] for reader 3 and 22 of 23 [96%] for reader 4; P = .065). Dose reduction averaged 50% (P < .001). In patients with breast cancer, PET/MR imaging may yield better sensitivity for liver and possibly bone metastases but not for pulmonary metastases, as compared with that attained with PET/CT, at about half the radiation dose.
登录
查看更多内容
影响因子：
2.6
作者：
Kitajima, Kazuhiro;Nakamoto, Yuji;Sugimura, Kazuro
通讯作者：
Sugimura, Kazuro
影响因子：
4.4
作者：
Raad, Roy A.;Friedman, Kent P.;Chandarana, Hersh
通讯作者：
Chandarana, Hersh
DOI：
10.1093/jnci/djs451
发表时间：
2012-12-19
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Groheux D;Hindié E;Delord M;Giacchetti S;Hamy AS;de Bazelaire C;de Roquancourt A;Vercellino L;Toubert ME;Merlet P;Espié M
通讯作者：
Espié M
影响因子：
1.3
作者：
Jeong, Ju Hye;Cho, Ihn Ho;Chun, Kyung Ah
通讯作者：
Chun, Kyung Ah
影响因子：
3.3
作者：
Pace, Leonardo;Nicolai, Emanuele;Salvatore, Marco
通讯作者：
Salvatore, Marco